SEC
PACB icon

Seven Eight Capital’s Pacific Biosciences PACB Stock Holding History

Seven Eight Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,538
Closed -$73.3K – 851
2024
Q1 		$73.3K Sell
19,538
-250,629
-93% -$1.47M 0.01% 581
2023
Q4 		$2.65M Buy
270,167
+28,911
+12% +$236K 0.31% 79
2023
Q3 		$2.01M Buy
241,256
+221,353
+1,112% +$2.53M 0.24% 112
2023
Q2 		$265K Sell
19,903
-48,648
-71% -$591K 0.04% 418
2023
Q1 		$794K Buy
+68,551
New +$682K 0.17% 168
2022
Q4 		– Sell
-47,806
Closed -$278K – 574
2022
Q3 		$278K Buy
+47,806
New +$274K 0.06% 397
2022
Q2 		– Sell
-157,308
Closed -$1.43M – 561
2022
Q1 		$1.43M Buy
157,308
+73,819
+88% +$850K 0.19% 164
2021
Q4 		$1.71M Buy
+83,489
New +$2.01M 0.31% 103
2020
Q4 		– Sell
-20,000
Closed -$197K – 572
2020
Q3 		$197K Buy
+20,000
New +$115K 0.04% 522

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seven Eight Capital's PACB Position: Q2 2024 in Review

Seven Eight Capital sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 19,538 shares — an estimated $73.3K sold.

Seven Eight Capital first reported a position in PACB in Q3 2020 and held it in 9 quarters. The position peaked at $2.65M in Q4 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Seven Eight Capital reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Seven Eight Capital sold 19,538 Pacific Biosciences shares in Q2 2024, an estimated $73.3K.
  • Seven Eight Capital first reported a position in Pacific Biosciences in Q3 2020 and held it in 9 quarters.
  • Seven Eight Capital's Pacific Biosciences position peaked at $2.65M in Q4 2023.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.